Myeloproliferative Neoplasms

Jamile Shammo, MD, FACP, FASCP, provides an overview of the different types of myeloproliferative neoplasms.

Stephen Oh, MD, PhD, and Ruben Mesa, MD, explain the fundamentals of essential thrombocythemia (ET) and its treatment options.

Angela Fleischman, MD, PhD, and Stephen Oh, MD, PhD, discuss polycythemia vera (PV) and the possible therapies that can be used to treat patients.

Jamile Shammo, MD, FACP, FASCP, tells how she would monitor ET and PV based on her personal experience.

The panel describes the possible outcomes for patients with myeloproliferative neoplasms (MPN).

Dr Fleischman provides details about myelofibrosis (MF) and what factors are considered with a diagnosis.

Drs Shammo and Mesa explain the MF prognosis and possible risk factors.

The panel continues the MF prognosis discussion while also discussing biomarkers and treatment for the disease.

A group of experts explain how to determine treatment for each patient with MF, as well as upfront therapy options.

More upfront therapy options for the MF treatment landscape are discussed, including the safety profiles of these drugs.

A panel of experts share how they select between treatment options for patients with MF.

The panel relays how they would sequence MF therapies, as well as the novel combination therapies that can be used.

Dr Oh lists the ways MF can and should be monitored.

Dr Fleischman explains the clinical course she would take with MF treatment and what it would take to change therapies.

A group of experts share unmet needs in the treatment of MPN and MF while providing information about potential advances that could impact treatment in the future.

The panel concludes this discussion with clinical pearls they would like to share with colleagues that treat MPN and MF.